Investigational drug · Phase 2
ONC206
Also called: JZP3507
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Meningioma, Advanced Pheochromocytoma and Paraganglioma, PCPG.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "ONC206"
First trial start
2026
Jan 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ONC206", any sponsor or status.
Conditions studied
As listed on its trial records.
- Meningioma
- Advanced Pheochromocytoma and Paraganglioma
- PCPG
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ONC206" as an intervention, largest first.
Sabine Mueller, MD, PhDAcademic, hospital or other
NCT04732065 · 208 participants (planned) · Start Aug 23, 2021 · Primary completion May 31, 2027
Drug: ONC206 · For: Diffuse Midline Glioma (DMG); Glioblastoma; Recurrent Ependymoma and 5 more
Sites: San Francisco, California; Washington D.C., District of Columbia; Atlanta, Georgia · 7 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07282587 · 90 participants (planned) · Start Jan 2, 2026 · Primary completion Dec 15, 2028
Drug: ONC206; ONC206: Dose 1 and 1 more · For: Advanced Pheochromocytoma and Paraganglioma; PCPG
Sites: Los Angeles, California; Palo Alto, California; Aurora, Colorado · 9 sites in all
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsActive, not recruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT04541082 · 35 participants · Start Oct 26, 2020 · Primary completion Mar 31, 2027
Drug: ONC206 · For: Central Nervous System Neoplasms; Glioblastoma; Gliosarcoma, Adult and 20 more
Sites: Bethesda, Maryland
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07533942 · 30 participants (planned) · Start Jul 16, 2026 · Primary completion Oct 25, 2028
Drug: JZP3507 · For: Meningioma
Sites: San Francisco, California; New Haven, Connecticut; Indianapolis, Indiana · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Single-nucleus profiling of postmortem diffuse midline gliomas identifies mitochondrial biogenesis as a resistance mechanism to imipridone therapy.
Okada M, Subramaniam B, Geng B, et al. · Neuro Oncol 2026
- Next-Generation Imipridones ONC206 and ONC212 Synergize with Lurbinectedin in Killing Pancreatic Ductal Adenocarcinoma Cells.
Tummala T, Su A, Uruchurtu ASS, et al. · bioRxiv 2026
- ClpP activation in high-risk medulloblastoma: ONC206 as a potent inducer of the integrated stress response and mitochondrial damage for a broader therapeutic window.
Hau P · Neuro Oncol 2026
- ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.
Tzaridis T, Liu J, Chien FL, et al. · Neuro Oncol 2026
- The Imipridone ONC206 Inhibits Tumor Growth and Improves Survival in Patient-Derived Xenograft Models of Uveal Melanoma.
Ali MM, Alauddin M, Mahmud I, et al. · Cancers (Basel) 2026
- Integrated Phenotypic and Transcriptomic Profiling Positions ONC212 as a Lead Imipridone in Androgen-Independent Prostate Cancer Models.
Ghamlouche F, Yehya A, Kurdi A, et al. · Int J Mol Sci 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Jazz Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.